Download Files:
ALK4290
$650 – $5,300
Products Details
Product Description
– ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3].
Web ID
– HY-136788
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C27H34ClN5O3
References
– [1]NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1.|[2]Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). May-Jun 2020; 9(3):250-259.|[3]Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic
CAS Number
– 1251528-23-0
Molecular Weight
– 512.04
Compound Purity
– 99.21
SMILES
– O=C(C1=CC(NC([C@@H](CC2)N(C3CCN(CC4=CC=C(Cl)C(C)=C4)CC3)C2=O)=O)=NC(C)=C1)N(C)C
Clinical Information
– Phase 2
Research Area
– Inflammation/Immunology; Neurological Disease
Solubility
– DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– CCR
Isoform
– CCR3
Pathway
– GPCR/G Protein;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
